O ovoj e-knjizi
This issue of Radiation Medicine Rounds discusses the more salient topics surrounding the role of radiation therapy for hematologic malignancies. There are literally dozens of distinct lymphoma subtypes, each with its own unique molecular and clinical features. Although systemic cytotoxic and targeted therapies have improved dramatically, radiation therapy remains an important modality for optimal clinical outcomes. With contributions from nationally recognized experts, Hematologic Malignancies offers an overview of the full spectrum of therapy for hematologic malignancies ranging from lymphoma and leukemia to plasma cell dyscrasias. Recent advances in radiotherapy for hematologic malignancies allow for maintenance of excellent local control with improvements in toxicity achieved through reductions in field sizes, in dose delivered, and increasingly conformal delivery techniques. Hematologic Malignancies provides the practitioner with a current overview of best practices, recent research, and future directions in the management of these complex cancers.
Otkrijte više
O autoru
Bouthaina S. Dabaja, MD, Associate Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Charles R. Thomas, Jr., MD is Professor and Chairman of the Department of Radiation Medicine and Professor of Hematology/Oncology at the Oregon Health & Science University Cancer Institute.
Michael Tomblyn, MD, MS, Assistant Member Radiation Oncology Moffitt Cancer Center & Research Institute, Tampa FL
Karen Winkfield, MD, PhD, Hematologic Malignancy Service, Department of Radiation Oncology, Massachusetts General Hospital
